摘要
结直肠癌(CRC)是世界范围内常见的消化道恶性肿瘤。近年来,中国的CRC发病率呈上升趋势,而确诊时多为中晚期,患者预后欠佳。随着多种靶向药物和免疫治疗相关临床试验的成功并获批用于CRC治疗,使晚期CRC患者的治疗和生活质量均有较大改善。本文在阐述中国晚期CRC治疗现状的基础上,对靶向和免疫治疗在晚期CRC中的研究进展进行了综述。
Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies in the world.In recent years,the incidence of CRC is on the rise in China,while the diagnosis is mostly in the advanced stage with poor prognosis.With the success of a variety of targeted drugs and immunotherapy-related clinical trials and approved for the treatment of CRC,the treatment and quality of life for patients with advanced CRC have been greatly improved.This article describes the treatment of advanced CRC in China,and reviews the progression of targeted and immunotherapy in advanced CRC.
作者
章余妹
邵莉
李进
Zhang Yumei;Shao Li;Li Jin(Department of VIP Clinical, Shanghai East Hospital of Tongji University, Shanghai 200120, China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第6期571-573,共3页
Chinese Clinical Oncology
基金
上海市科学技术委员会资助项目(ZR1430900)1
关键词
结直肠癌
靶向治疗
免疫治疗
Colorectal cancer
Targeted therapy
Immunotherapy
